Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

mRESVIA ®is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 /Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products ...

Moderna was dealt a significant blow in the patent battle over who owns the Covid-19 vaccine last week. In the U.S., the Cambridge drug and vaccine maker hit a roadblock when the Patent Trial and ...

Moderna's earnings beat was driven by strong vaccine demand and effective cost management. For fiscal 2024, analysts expect MRNA to report a loss per share of $9.27, 24.8% narrower from a loss per ...

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45 th Annual Health ...

the Department of Health and Human Services has confirmed that it is reevaluating a nearly $600 million contract issued to Cambridge, Mass.-based Moderna by the Biomedical Advanced Research and ...

Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around $130, and later that year it climbed as high as $449, as investors ...

CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted ...